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Abstract
Cyclic vomiting syndrome (CVS) is characterized by severe episodic emesis in adults 
and children. Cannabinoid hyperemesis syndrome is an increasingly recognized CVS‐
like illness that has been associated with chronic cannabis use. There are significant 
gaps in our understanding of the pathophysiology, clinical features, comorbidities, 
and effective management options of CVS. Recommendations for treating CVS are 
based on limited clinical data, as no placebo‐controlled, randomized trials have yet 
been conducted. Diseases associated with CVS, including migraine, mitochondrial 
disorders, autonomic dysfunction, and psychiatric comorbidities, provide clues about 
pathophysiologic mechanisms and suggest potential therapies. We review our cur‐
rent understanding of CVS and propose future research directions with the aim of 
developing effective therapy. Establishing a multicenter, standardized registry of 
CVS patients could drive research on multiple fronts including developing CVS‐spe‐
cific outcome measures to broaden our understanding of clinical profiles, to serve 
as treatment end points in clinical trials, and to provide a platform for patient re‐
cruitment for randomized clinical trials. Such a robust database would also facilitate 
conduct of research that aims to determine the underlying pathophysiological mech‐
anisms and genetic basis for CVS, as well as identifying potential biomarkers for the 
disorder. Soliciting government and industry support is crucial to establishing the 
necessary infrastructure and achieving these goals. Patient advocacy groups such 
as	the	Cyclic	Vomiting	Syndrome	Association	(CVSA),	which	partner	with	clinicians	
and researchers to disseminate new information, to promote ongoing interactions 
between patients, their families, clinicians, investigators, to support ongoing CVS re‐
search and education, must be an integral part of this endeavor.
K E Y W O R D S
Cannabinoids, cyclic vomiting, migraine headaches, multicenter registry, psychosocial 
dysfunction
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1  | INTRODUC TION
The preceding articles in this Supplement of Neurogastroenterology 
and Motility have detailed what is known about the clinical features, 
diagnosis, and management of cyclic vomiting syndrome (CVS) and 
a related disorder, cannabinoid hyperemesis syndrome (CHS), in 
adult patients. Formal diagnostic criteria for CVS in adults were not 
defined until publication of the Rome III consensus statements in 
2006.1 The CVS criteria were subsequently revised in 2016 by the 
Rome IV committee, based mostly on expert consensus, rather than 
rigorous investigation between successive versions.2 The Rome IV 
process also published new criteria for CHS which are discussed 
elsewhere in this supplement.
Our understanding of CVS in adults is derived largely from ret‐
rospective studies conducted at tertiary care centers. Needless 
to say, numerous critical knowledge gaps remain and pose signifi‐
cant barriers for developing effective management options for the 
treatment of CVS. Progress has been limited by the relatively re‐
cent recognition of CVS in adults, lack of widespread knowledge 
about CVS in the medical community resulting in misdiagnosis and 
delayed diagnosis, lack of standardized database information, and 
low‐quality evidence on available treatment options. Even a clinical 
feature as rudimentary as the prevalence of CVS in adults is not 
well established. Most clinicians consider CVS in adults to be rare, 
but	a	recent	report	calculated	a	prevalence	of	10.8%	among	outpa‐
tients in a specialty gastroenterology clinic, a rate that approaches 
that of gastroparesis, chronic constipation, and irritable bowel syn‐
drome in tertiary outpatient cohorts.3‐6 However, another recent 
population-based	 survey	 estimated	 a	 lower	 prevalence	 of	 2%	 of	
CVS in adults.7 While these preliminary estimates are important, 
determining the actual prevalence of CVS in adults has funda‐
mental implications for allocation of funding and future research. 
Treatment trials in CVS would be facilitated by recruitment into a 
national clinical registry of patients who are well‐phenotyped using 
standardized criteria. By virtue of its size and robust data structure, 
such a resource would permit performance of randomized, con‐
trolled trials (RCTs) of novel CVS therapies—an area lacking in the 
current literature. Even in children with CVS, only one recent RCT 
was published reporting comparable effectiveness of amitriptyline 
and cyproheptadine.8
2  | PATHOPHYSIOLOGY AND COMORBID 
CONDITIONS
To better design mechanism‐driven management approaches, it is 
essential that we elucidate the pathogenesis, clinical features, and 
disease	associations	 in	CVS.	Acquisition	of	such	 information	could	
provide answers to several intriguing questions such as Why do CVS 
patients only periodically experience symptoms? How are CVS epi‐
sodes triggered? What is the reason for the heterogeneity in sever‐
ity of CVS symptoms? and Why do some patients respond to certain 
medications such as amitriptyline while others do not? These are a 
few	examples	of	research	questions	to	be	answered.	A	viable	CVS	
model must consider the diversity of attack triggers and the breadth 
of prodromal symptoms experienced at the onset of CVS episodes. 
Ideally, any disease model should also provide an ability to predict an 
individual's disease course.
Cyclic vomiting syndrome is, by definition, a syndrome with ep‐
isodic bouts of uncontrollable vomiting, separated by periods of 
relative wellness. These attacks are often accompanied by other 
symptoms including intense nausea, abdominal pain, headaches, 
photo‐ and phonophobia, and several autonomic symptoms simi‐
lar	 to	 those	observed	 in	migraine	headache.	As	with	most	disor‐
ders defined by characteristic symptom profiles, CVS is probably 
not driven by a single pathogenic mechanism. Rather, it is useful 
to conceptualize its pathogenesis as resulting from the cumulative 
interaction of unique combinations of a number of distinct pheno‐
typic processes and comorbid conditions leading to cyclical emesis 
(Figure 1). Viewed in this way, the similarity of CVS to other pe‐
riodic disorders such as migraine and epilepsy offers clues about 
potential phenotypes that may lead to the development of CVS 
in adults. Other periodic disorders such as migraines, seizures, or 
panic attacks appear to have a “threshold” above which triggers 
can elicit attacks. Similarly, CVS may have an “attack threshold” 
that when breached by different mechanisms is capable of elicit‐
ing repetitive vomiting in susceptible patients.9 These thresholds 
may differ widely among patients. Hence, the key to developing 
effective, personalized treatments for CVS hinges on recognizing 
disease triggers and mechanisms and raising the individual thresh‐
old for developing symptoms. The diversity of pathways may either 
reflect the presence of specific subtypes of CVS (eg, catamenial, 
hypothalamic surge, and CHS), distinct genetic predispositions (eg, 
RYR2 gene encoding a stress‐induced neuronal calcium channel 
polymorphisms), and/or a sensitivity to distinct symptom triggers 
(eg, psychological stressors and hypoglycemia).10‐14 In order to de‐
velop targeted CVS therapies, future research needs to define CVS 
subtypes based on mechanistic definitions, rather than solely on 
symptom criteria.
Key Points
• Cyclic vomiting syndrome (CVS) has associations with 
migraines, lifestyle and psychosocial factors, neuro‐
humoral contributors, and cannabis use; treatment re‐
mains empiric based on small case series.
• Gaps persist in understanding the pathophysiology, 
comorbidities, and effective therapies of CVS and a re‐
lated disorder—cannabinoid hyperemesis syndrome.
•  Goals of future CVS research should include validating 
CVS‐specific symptom and quality of life instruments and 
establishing an infrastructure to permit multicenter data 
acquisition, investigation of disease mechanisms, and fa‐
cilitation of patient recruitment for treatment trials.
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2.1 | CVS as a putative neurogenic disorder
Cyclic vomiting syndrome shares clinical features with central nerv‐
ous system (CNS) disorders such as migraine, in which episodic 
symptoms are triggered by various stimuli, and is followed by qui‐
escent, largely asymptomatic intervals. Both CVS and migraine at‐
tacks can be triggered by acute psychological or physiological stress, 
sleep deprivation, and menses.9,14,15	A	personal	or	family	history	of	
migraine disorder is the most prominent CNS comorbidity in CVS, 
with	24%-70%	of	adults	reporting	this	association.16,17 It is important 
to recognize that many migraine sufferers report prominent nausea 
and vomiting with their headaches. CVS also shares some clinical 
features with epilepsy and even panic disorder.14,18 The compelling 
clinical connection between migraine, panic, and CVS suggests that 
CVS is a neurogenic disorder.
Neuronal hyperexcitability may represent a common link be‐
tween CVS and other episodic CNS disorders.19‐21 Hyperexcitability 
may be a consequence of genetic variants in ion channel and/or neu‐
rotransmitter receptor structure and function, or may result from 
aberrant development of neural circuits. The specific neural circuits 
for nausea and vomiting within higher centers of the brain are be‐
ginning to be elucidated using functional imaging methods in human 
subjects. Studies delineating alterations in brain network functional 
connectivity, particularly within networks involving the amygdala 
and the insular cortex, may further explain the role of brain abnor‐
malities in CVS.22 It is possible that neuronal hyperexcitability and 
a lowered threshold to trigger specific patterns of neural activity 
within these cortical and subcortical circuits are pathogenic features 
of CVS. These concepts may partly explain the clinical benefits of 
anticonvulsant and antimigraine therapeutics in CVS.9 Improving 
our understanding of these pathophysiologic factors in well‐defined 
CVS populations may translate into development of novel and/or 
personalized CVS therapies.
2.2 | Genetic factors in CVS
Cyclic vomiting syndrome, migraines, and epilepsy all share links to 
some form of mitochondrial dysfunction. This dysfunction could be 
subclinical at baseline but exacerbated by physiological stressors 
such as an acute systemic illness. Some genetic links to mitochon‐
drial dysfunction have been demonstrated in pediatric CVS, such as 
mitochondrial	DNA	polymorphisms	(16519T,	3010A)	or	other	mito‐
chondrial	DNA	deletions.23‐25 The functional significance of these 
single nucleotide polymorphisms (SNPs) remains unknown. Further, 
these mitochondrial associations have not been replicated in adults 
with CVS suggesting the role of other non‐mitochondrial factors 
in adult CVS patients. Inborn errors of metabolism, including fatty 
acid oxidation disorders and urea cycle defects, have been associ‐
ated with pediatric CVS.26 Recent studies found that ion channel 
polymorphisms	(RYR2,	SCN4A)	that	impact	cellular	stress	responses	
may be associated with CVS.13	The	synergic	 roles	of	nuclear	DNA	
mutations (identified by NextGen sequencing) that impact the func‐
tion of ion channels, axonal transport (KIF1B), or energy production 
(TRAP1)	have	been	investigated	in	children	with	CVS.13,23,25 Larger 
genetic and functional studies of CVS in both adults and children will 
be needed to better establish the heritable basis of this disorder. It 
is critical that these studies involve well‐characterized patient sub‐
sets in order to better delineate genotype‐phenotype relationships. 
F I G U R E  1   Proposed pathophysiologic model of CVS. This model of adult CVS development envisions contributions from multiple 
phenotypic factors that collectively lead to a final common clinical presentation of episodic emesis and other comorbid conditions seen in 
CVS. Genetically predetermined and other factors may be modified by life experiences, chronic stress, or drug abuse
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As	an	example,	a	patient	with	hypoglycemia-triggered	CVS	attacks	
might be more likely to have genetically determined mitochondrial 
dysfunction than an individual with CVS attacks provoked primarily 
by psychological stressors.
2.3 | Cannabinoids in CVS and CHS
It remains to be determined whether CHS is a disorder truly distinct 
from CVS or is a subtype of CVS. Both CVS and CHS have common 
clinical presentations except for a history of chronic, regular can‐
nabis use preceding the onset of CVS‐like episodes in CHS. There 
is considerable variation in the application of diagnostic criteria 
for CHS, and the diagnosis remains inconsistent between centers. 
However, creating a precise definition of CHS is difficult for a few 
reasons. Firstly, the duration, potency, and amount of cannabis use 
needed to elicit CHS are not well established. Furthermore, vari‐
ous cannabis products contain wide‐ranging concentrations of can‐
nabinoid mixtures, and it is not known which compound(s) drive the 
development of CHS. Thus, given the general lack of regulation and 
heterogeneity of cannabis products that are available, it is difficult 
to quantify the true exposure to any one cannabinoid compound in 
a given CHS patient. The relatively high potency of modern cannabis 
products	(with	generally	higher	∆9‐tetrahydrocannabinol [THC]‐to‐
cannabidiol [CBD] ratios) may result in cannabinoid (CB1) receptor 
downregulation	 resulting	 paradoxically	 in	 emesis.	 Again	 as	 with	
CVS, it is plausible that a certain threshold needs to be breached 
by a multitude of factors that may explain the periodic nature of 
symptoms.
Preliminary data in CVS indicate that the endocannabinoid sys‐
tem (ECS) is involved in the pathophysiology of CVS. Serum levels of 
endocannabinoid‐related lipids (N‐oleoylethanolamine and N‐palmi‐
toylethanolamide) are higher during the emetic phase of CVS than 
during the inter‐episodic phase.27	Recently,	 the	AG	and	GG	geno‐
types of CB1	receptor	rs806380	were	associated	with	an	increased	
risk of CVS while the CC genotype of CB1	receptor	rs806368,	and	
AG	and	GG	genotypes	of	mu-opioid	 receptor	 rs1799971	were	as‐
sociated with a decreased risk of CVS.28 This highlights a potential 
genetic basis for ECS dysregulation at the receptor level rather than 
an absolute deficiency of endocannabinoids in CVS and may indicate 
that some individuals may be genetically predisposed to develop cy‐
clical emesis when chronically exposed to cannabis. Taken together, 
these observations suggest a role for the ECS in CVS and CHS with 
both genetic (ie, CB1 receptor SNPs) and environmental (ie, expo‐
sure to high potency cannabis products) factors altering stress re‐
sponses that may contribute to the development of core CVS/CHS 
symptoms.
2.4 | Autonomic and neuroendocrine dysfunction 
in CVS
Autonomic	or	neuroendocrine	disturbances	appear	to	be	important	
phenotypes	that	are	associated	with	CVS.	An	upregulated	hypotha‐
lamic-pituitary-adrenal	 (HPA)	 axis	 has	 been	 observed	 during	 CVS	
episodes in a subset of children described by Sato et al11 and one 
adult.	HPA	hyperresponsiveness	may	drive	the	release	of	corticotro‐
pin‐releasing factor (CRF) which has potent actions on proximal gut 
motility.29 However, most studies measured CRF in the periphery, 
and it remains unclear how central CRF plays a role in CVS.
Many adults with CVS exhibit sympathetic nervous system 
dysregulation.30‐32 Postural orthostatic tachycardia, abnormal 
thermoregulatory sweat studies, and aberrant heart rate variability 
measurements have all been associated with CVS, but it is uncer‐
tain whether CVS treatment alters these parameters.30 Patients 
with CVS also have varied gastric motility patterns which include 
accelerated	 (59%),	 normal	 (27%),	 and	 delayed	 gastric	 emptying	
(14%)	 during	 inter-episodic	 intervals	 of	 the	 illness.33	 Accelerated	
gastric emptying may in fact be a surrogate marker for underly‐
ing autonomic dysfunction in CVS. Further, delayed gastric emp‐
tying should not be interpreted as gastroparesis particularly in the 
setting of typical episodic vomiting and could be explained by the 
use of chronic cannabis and opioids. For example, a previously de‐
scribed cohort of patients with cyclic gastroparesis may have sim‐
ply had undiagnosed CVS. It is particularly important to perform 
gastric emptying studies during the inter‐episodic phase to allow 
for any meaningful interpretation.
2.5 | Impact of stress on manifestations of CVS
Patterns of neuroendocrine and autonomic dysfunction in CVS may 
reflect aberrant CNS regulation of “allostasis,” the process by which 
the body responds to stressors to regain homeostasis. Impaired al‐
lostatic regulation is observed with mood disorders, chronic stress, 
drug abuse, and other CNS illnesses.34 The cumulative impact of 
chronic stress, or “allostatic load,” can be measured over time using 
physiological and serum biomarkers including neuroendocrine (eg, 
stress hormones), metabolic (eg, serum lipids), immunologic (eg, au‐
toimmune), cardiovascular (eg, vital signs), and anthropometric (eg, 
body mass) factors.35 It is logistically difficult to characterize physi‐
ological changes during the prodromal or active emetic phases of 
CVS, but longitudinal studies of allostatic regulation in CVS can still 
be informative when performed during the inter‐episodic phase. 
Future studies employing wearable sensor technologies will define 
whether changing patterns of stress, cognitive/emotional events, 
physical activity, sleep patterns, and autonomic reactivity measured 
during inter‐episodic (and potentially prodromal) phases can serve as 
predictive biomarkers for CVS episodes.
High levels of perceived stress can trigger episodes of CVS, mi‐
graines, seizures, and panic attacks, which share one or more phe‐
notypic factors, raising the possibility that these conditions have a 
common CNS pathway.9,14,17 Negative life experiences are known 
to shape the development of neural circuits for cognitive and emo‐
tional processing, and such neural plasticity may in turn lead to 
CVS attacks that are more easily triggered. Thus, a cognitive vul‐
nerability to stressors may be an important phenotype shared be‐
tween CVS and other stress‐sensitive disorders. Future research 
should characterize the psychological traits and cognitive biases 
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that contribute to the stress sensitivity of CVS attacks. The role 
of lifestyle factors including stress management, consistent sleep 
routines, regularly scheduled meals, maintenance of hydration, 
regular exercise, and identification of episode triggers, factors that 
have been implemented in migraine prevention, may provide ad‐
ditional insight into CVS episode prevention.36,37 Understanding 
these relationships may provide a rational basis for using psycho‐
logical or mind‐body interventions to influence the disease course 
in CVS.
3  | PSYCHIATRIC COMORBIDIT Y IN C VS
Psychiatric disorders are considered separately from other comor‐
bidities	given	their	prominence	in	CVS.	Anxiety,	panic,	and	depres‐
sion are commonly reported in adults with CVS.10,38 However, few 
studies in adult CVS have used standardized diagnostic interviews 
to ascertain psychiatric disorders, which is the gold standard for 
psychiatric research. Rather, most studies that report the pres‐
ence of psychiatric conditions in CVS have employed either patient 
report, chart review, or other screening instruments. The lack of 
standardized evaluation of psychiatric comorbidities, the low num‐
bers of CVS patients in individual studies, and the potential bias 
from tertiary care patient samples make it difficult to accurately 
calculate the true prevalence of psychiatric conditions in the adult 
CVS population. It will be important in future studies to systemati‐
cally evaluate patients for the presence of psychiatric disorders, as 
such	conditions	likely	influence	the	disease	course.	As	an	example,	
one case report found that persistent nausea provoked anxiety, 
leading to conditioned, anticipatory nausea and vomiting that in 
turn aggravated the patient's CVS course.39 The relevance of psy‐
chiatric factors to clinical presentations in different CVS subsets 
warrants further characterization.
Population studies have found anxiety and depressive disorders 
to be independently associated with many physical conditions such 
as hypertension, arthritis, thyroid disease, migraine, fibromyalgia, 
respiratory, cardiovascular, and gastrointestinal disorders, and this 
comorbidity is significantly associated with poor quality of life and 
disability in affected adults.40 In similar fashion, it is likely that the 
presence of such psychiatric comorbidities would impact the func‐
tional status and quality of life of adults with CVS independent of 
their primary CVS symptoms.
4  | FUTURE RESE ARCH DIREC TIONS IN 
C VS
In addition to providing details about clinical and pathophysiologic 
features, future investigation in CVS should include high‐quality 
trials to confirm the benefits of existing and future CVS therapies. 
These efforts will have a greater likelihood of success with collabo‐
ration of clinical investigators across multiple medical centers that 
also include engagement with community providers.
4.1 | Data acquisition
Further investigation into characterizing CVS epidemiology and sub‐
phenotypes will require the conduct of clinical trials that validate the 
development of a CVS‐specific symptom score, quality‐of‐life as‐
sessment, and resource utilization questionnaires. Creation of a large 
national database of well‐characterized CVS patients using these 
instruments should be linked to a standardized electronic medical 
record platform to support these research objectives. Instruments 
such	 as	 the	 Patient	 Assessment	 of	 Upper	 Gastrointestinal	
Disorders	 Symptoms	 (PAGI-SYM)	 survey,	 Gastroparesis	 Cardinal	
Symptom Index (GCSI), Leeds Dyspepsia Survey, and Daily Diary of 
Gastroparesis Symptoms (GSDD) have been employed to quantify 
symptom severity in database analyses of other disorders of chronic 
nausea and vomiting.41 However, such instruments include recall 
time frames of up to several weeks and assume relatively stable, 
continuous symptoms and likely are inappropriate for CVS trials, 
which would require instruments that are responsive to brief, dis‐
crete episodes lasting hours to days separated by prolonged, asymp‐
tomatic inter‐episodic intervals. Recently developed questionnaires 
such as the Patient‐Reported Outcomes Measures Information 
System (PROMIS) in gastroenterology may also not have recall pe‐
riods that are long enough to be meaningful for CVS studies.42,43 
Similarly, quality‐of‐life instruments for CVS should address unique 
features of CVS including periodicity, variable intervals between 
episodes,	 and	 impact	on	 activities	of	 daily	 living.	Additionally,	 use	
of standardized psychological surveys in large CVS populations will 
enhance understanding of the impact of psychosocial dysfunction 
on CVS severity as has been done for other conditions with chronic 
nausea and vomiting such as gastroparesis.44
Given these constraints, novel symptom, quality of life, psycho‐
social, and disease‐related disability instruments could be adapted 
from existing instruments from episodic disorders related to CVS, 
such	as	migraine.	One	example	is	the	Migraine	Disability	Assessment	
(MIDAS)	which	assesses	functional	impairment	associated	with	mi‐
graine.45 Likewise, the development of resource utilization measures 
including emergency department visits, hospitalizations, medication 
usage, and healthcare costs should consider variable attack frequen‐
cies between patients and include longer observation periods ex‐
tending up to 12 months. Defining healthcare utilization patterns of 
CVS patients and their resource costs will be critical to help secure 
research funding from foundation and governmental organizations. 
In addition, research directed at improving patient management pro‐
tocols and emergency department protocols hold promise of low‐
cost, high‐impact changes to the patient experience.
In addition to acquiring new information from validated survey 
instruments, it will be useful to adopt a standardized panel of bio‐
markers from patient specimens to gain insight into CVS pathophys‐
iology. Studies in small cohorts employing blood, urine, and saliva 
samples to quantify neurohumoral and metabolic functions and ge‐
netic	profiles	of	mitochondrial	DNA	and	 ion	channel	distributions,	
and functional MRI imaging methodologies to discern altered CNS 
signaling have identified factors which may be of importance in 
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some CVS subsets.11,13,20,22‐26 Broad‐based application of biomarker 
panels including these and other testing across multiple centers in 
diverse CVS patient populations will delineate the relevance of these 
and other parameters in modifying the clinical presentation of this 
disorder.
4.2 | Expanded understanding of pathophysiology
A	critical	component	 to	better	understanding	CVS	and	CHS	 is	 the	
acquisition of more definitive data on the pathophysiology of these 
conditions (Table 1).Definition of underlying mechanisms for symp‐
toms and its triggers will allow clinicians and patients to better pre‐
dict and avoid triggers of CVS episodes. The role of genetic factors 
such	 as	mitochondrial	 DNA,	 ion	 channels,	 neurohumoral	 function	
(endocannabinoid system and the hypothalamic‐pituitary‐adrenal 
axis), and neurogenic contributors in CVS development needs to be 
studied systematically. This will be crucial for the development of 
targeted therapies in CVS, which are now solely symptom‐based. 
This comprehensive information base relating to CVS and CHS 
pathophysiology may identify new directions to pursue in treating 
these challenging conditions.
4.3 | Detailed profiling of clinical features
Acquisition	 of	 comprehensive	 assessments	 of	 clinical	 features	
of CVS and CHS patients across centers in prospective fashion 
will provide essential new details about manifestations of these 
conditions (Table 1). Defining the prevalence of disorders as‐
sociated with CVS and CHS in relation to other conditions simi‐
larly characterized by unexplained chronic vomiting should help 
clinicians who are initially evaluating an undiagnosed patient. 
Characterizing demographic and comorbid features of CVS will 
permit greater distinction from other functional disorders includ‐
ing chronic nausea and vomiting syndrome (CNVS).2 Furthermore, 
such information may help to determine whether unusual cases 
of coalescent CVS are distinct from CNVS and should be man‐
aged differently or whether they represent a merging of the two 
functional gastroduodenal disorders which would then be offered 
common	 management	 approaches.	 Adoption	 of	 standardized	
psychological questionnaires will permit better understating of 
psychiatric	comorbidities	in	CVS.	An	exhaustive	clinical	database	
providing greater clarity on different CVS subtypes (eg, catamenial, 
migraine‐associated, stress‐related, and CHS) will offer a founda‐
tion for further investigation to determine whether any subtype 
warrants consideration of dedicated therapies. In particular, im‐
proved data collection on suspected CHS patients will determine 
whether CHS truly mimics CVS in the quantitative aspects of its 
cyclical emetic profile, whether there are undefined risk factors 
relating to its development, and whether only cannabis cessation 
is effective for controlling the condition. The data provided by 
these efforts will provide support for future revision of diagnostic 
criteria for CVS and CHS in evidence‐based fashion by the Rome 
Foundation and other organizations. Finally, comprehensive delin‐
eation of inpatient and outpatient resource utilization across cent‐
ers will emphasize the impact of CVS on both affected patients 
and families and the healthcare infrastructure to support efforts 
to obtain external funding for CVS treatment protocols.
4.4 | Treatment trial priorities
There is a great need to identify and validate therapies to develop 
better prophylaxis measures and to abort acute emetic episodes in 
CVS (Table 2). The healthcare costs due to hospitalizations from CVS 
are high amounting to $200 million annually based on a nationwide 
inpatient sample.46 This number does not include the additional 
staggering costs associated with medication therapies, emergency 
department care, outpatient visits and procedures, and lost time 
at work or in schooling due to CVS. These observations under‐
score the need for developing effective and safe therapies in CVS 
and reducing healthcare utilization. Deficiencies of existing small, 
single‐center case series include poor patient characterization, a 
lack of validated instruments to quantify symptoms and healthcare 
utilization, and a failure to conduct trials in a controlled fashion. 
Several issues must be considered when designing CVS treatment 
trials and barriers to conducting such trials should be acknowledged. 
Such treatment trials should consider both outpatient preventative 
protocols in addition to abortive therapies to be taken at home and 
parenteral treatments provided in an outpatient setting such as an 
infusion clinic or urgent care center, the emergency department, and 
in an inpatient setting. Furthermore, these trials should look at the 
organization and processes of care as well as the comparative ef‐
ficacy of multidrug protocols for well‐defined subsets of patients.
The experience of performing controlled trials of tricyclic agents 
for other functional gastrointestinal disorders has been illuminating. 
TA B L E  1   Research directions to define clinical features and pathophysiology of cyclic vomiting syndrome
Clinical features Pathophysiology
• Define CVS and CHS prevalence
• Distinguish CVS and CHS from other functional GI disorders with 
chronic vomiting
• Determine relationship of CHS to CVS
• Clarify features of other CVS subsets (eg, catamenial, migraine‐as‐
sociated, stress‐related, and cannabis‐related)
• Characterize psychosocial impact of CVS and CHS
• Quantify healthcare resource utilization
• Elucidate mechanisms of CVS episodes
•	 Identify	biomarkers	in	CVS	:	mitochondrial	DNA,	ion	channelopathy,	
and neurohumoral and neurogenic factors
• Clinical testing to assess importance of altered CNS processing, 
autonomic nervous system dysfunction, and gastric myoelectric and 
motor disturbances
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More than 5 years were required to enroll 216 patients with severe 
functional bowel disorders into a controlled trial of the tricyclic drug 
desipramine.47 Despite this prolonged recruitment, the trial did not 
show statistically significant benefits on intention‐to‐treat analyses 
(P = 0.16). Likewise, recruitment spanned more than 6 years in a trial 
to compare the effects of amitriptyline to escitalopram or placebo in 
292 patients with functional dyspepsia.48 In a clinical setting of most 
closely mimicking CVS, subject recruitment proceeded for more 
than 3 years to enroll 130 patients into a negative placebo‐con‐
trolled trial of nortriptyline in idiopathic gastroparesis.49 The only 
published RCT of amitriptyline in CVS employed cyproheptadine as 
the comparator in a total of 64 children.8 The main observation of 
this study was the non‐superiority of one therapy over the other 
over 12 weeks, but the actual efficacy of either treatment above 
placebo (or no therapy at all) was not proven. Given these observa‐
tions	and	the	fact	that	TCAs	appear	to	be	among	the	most	effective	
agents used for CVS prophylaxis, such trials in CVS may require a 
longer	duration	of	time	for	adequate	recruitment;	also,	if	such	TCA	
trials in CVS are considered, extended observation periods up to for 
6‐12 months may be required.
It would be prudent to pursue trials of more recently approved 
agents with fewer side effects as potential prophylactic therapies. 
Newer agents such as NK1 receptor antagonists have been found 
to be effective in CVS in children and adolescents based on a single 
TA B L E  2   Potential future therapeutic targets for treating cyclic vomiting syndrome
Type of therapy Category Specific therapy Proposed mechanisms of action
Prophylactic 
therapies
Anticonvulsants Topiramate Sodium	and	calcium	channel	blockade,	GABA-A	
receptor interaction
Zonisamide Sodium and T‐type calcium channel blockade
Levetiracetam Presynaptic calcium channel inhibition
Lamotrigine Sodium channel blockade suppress glutamate/aspar‐
tate release
Gabapentin Calcium channel interaction
Pregabalin Calcium	channel	interaction,	GABA	analog
Prophylactic antimi‐
graine agents
Telcagepant CGRP receptor antagonist
Erenumab CGRP receptor antagonist
Ubrogepant CGRP receptor antagonist
Fremanezumab Monoclonal antibody against calcitonin‐related 
polypeptides
Galcanezumab Monoclonal antibody against calcitonin‐related 
polypeptides
Tonabersat Gap junction modifier
Perampanel Ionotropic glutamate receptor antagonist
Antidepressant/atypical	
neuroleptic
Amitriptyline Tricyclic antidepressant inhibits reuptake of serotonin 
and norepinephrine
Mirtazapine CNS 5‐HT1A agonism, 5‐HT2 antagonism, 5‐HT2C 
inverse agonism, 5‐HT3 antagonism, a2 antagonism, 
H1 inverse agonism
Olanzapine 5‐HT2 inverse agonism, 5‐HT3 antagonism, M1 an‐
tagonism, M3 antagonism, D2 antagonism, H1 inverse 
agonism
Behavioral Cognitive behavioral therapy Reduced cognitive distortions (including 
catastrophizing)
Meditation Unknown
Abortive	
therapies
Antiemetics Aprepitant NK1 receptor antagonist
Rolapitant NK1 receptor antagonist
Investigational NK1 antagonists NK1 receptor antagonists
Abortive	antimigraine	
agents
Nasal/injectable sumatriptan 5‐HT1B/1D receptor agonist
Other triptans 5‐HT1B/1D receptor agonists
Miscellaneous 
medications
Topical capsaicin TRPV1 receptor interaction
Ketamine NMDA	receptor	antagonist
Candesartan Angiotensin	II	receptor	antagonist
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retrospective study and clinical experience, but there are no RCTs 
examining the efficacy in CVS in adults.50 Such trials would expand 
the treatment options available and enable us to better tailor ther‐
apy for individual patients. For instance, a patient who is obese may 
prefer	 not	 to	 use	 an	 agent	 that	 can	 cause	weight	 gain	 like	 a	 TCA	
versus a patient with profound weight loss who may benefit from 
such	therapy.	A	single-center	case	series	reported	reductions	in	CVS	
episode severity and frequency with the antiepileptic drugs zonis‐
amide and levetiracetam in patients failing tricyclic medications.51 
Others have reported a beneficial impact of the antiepileptic medi‐
cation topiramate when used as CVS prophylaxis.52 Data supporting 
these specific prophylactic measures are described in the preceding 
articles in this supplement of Neurogastroenterology and Motility. 
Newer therapies that target CGRP receptors have shown efficacy 
in migraine prophylaxis in Phase IIb and III trials, and erenumab and 
fremanezumab	have	recently	been	approved	by	the	FDA	for	this	in‐
dication.53,54 These medications have not been studied in CVS, but 
may be effective in those with or without migraine headaches given 
the strong link between CVS and migraine.55 Goals of future pro‐
spective investigations would be to confirm utility of any of these 
proposed therapies in reducing the frequency, duration, or severity 
of CVS attacks and to better define which patient subsets are likely 
to respond to different treatment options.
Likewise, better options are needed for aborting CVS attacks 
once started. The NK1 receptor antagonist aprepitant appears to 
have beneficial effects in pediatric CVS patients, with mounting clin‐
ical experience suggesting a major benefit in adult CVS patients as 
well;50 also, aprepitant was found to improve several outcome end 
points relating to nausea, vomiting, and other symptoms to greater 
degrees than placebo in 126 patients with gastroparesis symp‐
toms.56 Furthermore, given the association of migraines with CVS, 
efforts should be made to assess benefits of antimigraine therapies 
to abort attacks in adult CVS patients. In particular, controlled tri‐
als of 5‐HT1B,1D receptor agonists including intranasal sumatrip‐
tan should be considered for controlling acute emetic episodes in 
CVS. Coupled with controlled trials for CVS prophylaxis, defining a 
broader set of abortive therapies for CVS flares will permit confident 
definition of a data‐driven management approach to this disorder.
4.5 | Research infrastructure
The existing research infrastructure is not adequate to address these 
research needs in CVS. To further our understanding of the clinical 
features, pathophysiology, and management of CVS, it will be nec‐
essary to construct collaborative relationships between clinicians 
and investigators across a diverse and large number of academic 
and community institutions and patient support groups such as the 
CVSA.	Generating	a	multicenter	 registry	of	 large	numbers	of	CVS	
patients from broad backgrounds and managed in heterogeneous 
practices could provide details on the longitudinal course of CVS and 
function as a source of recruitment for controlled medication trials. 
Data entered into such a CVS registry would need to be standard‐
ized across centers to guarantee its quality using validated symptom, 
quality	of	life,	and	resource	usage	instruments	as	described	above.	A	
model for such a structure is the National Institutes of Health (NIH)‐
funded Gastroparesis Clinical Research Consortium, which has been 
functioning for more than a decade. Prior to construction of this 
Consortium, research in gastroparesis exhibited many features simi‐
lar to those which plague current CVS investigations. Since the con‐
sortium began recruitment, more than 1000 gastroparesis patients 
have been enrolled in longitudinal databases and three major pro‐
spective studies enrolling more than 100 patients each have been 
conducted.49,55,56 Longitudinal demographic and clinical data relat‐
ing to age, sex, symptom duration,48,56,57 traumatic events preceding 
symptom onset such as early adverse life events, both physiologi‐
cal and psychological, comorbid illnesses, associated psychological 
dysfunction, disease‐specific quality of life, healthcare resource 
utilization (including hospitalizations and emergency department 
visits), and prior and ongoing treatments have been systematically 
collected in all enrolled patients. In addition to organizing clinical 
data, establishing a biobank with collection of specimens in a cen‐
tral repository will greatly facilitate translational research that will 
contribute to our understanding of the underlying pathophysiology. 
This will enable us to identify novel biomarkers to make an accurate 
diagnosis and predict response to therapies. Examples of such mod‐
els which have been highly successful include both organic disorders 
such as inflammatory bowel disease58 and functional GI disorders 
such as gastroparesis. Novel factors relating to islet cell autoanti‐
bodies and heme oxygenase‐1 gene polymorphisms were identified 
in gastroparesis.59,60 Constructing databases of similar structure for 
CVS would be pivotal in changing the current paradigm of diagnosis 
and treatment of CVS.
A	single-center	 foundation	 for	 such	activities	 in	CVS	already	
has been generated. It should be recognized that, collectively, two 
of the authors of this article from one institution (BL and TV) have 
entered approximately 2000 adult and pediatric CVS patients in 
clinical databases, parts of which are stored in REDCap (Research 
Electronic Database Capture).61 REDCap is a secure online plat‐
form for building and managing databases in which data from 
electronic medical records can be imported and shared across in‐
stitutions. Funding from public and private sources is needed to 
organize a national registry and provide the necessary infrastruc‐
ture to foster collaborative, multicenter research. These efforts 
will be crucial to understanding the pathophysiology, conducting 
robust clinical trials, and determining longitudinal outcomes all of 
which will serve to improve patient outcomes. This will be facili‐
tated	by	patient	support	organizations	such	as	the	CVSA	and	par‐
ticipation by community providers.
Although	 industry	 support	would	be	unlikely	 for	 established	
therapies using generic drugs such as tricyclic antidepressants or 
older antiemetic classes, corporate funding could be sought for 
RCTs of newer antiepileptic agents, NK1 receptor antagonists, 
5‐HT1B,1D receptor agonists, or newer antimigraine therapies. 
Support from governmental agencies such as the NIH will also be 
critical	for	future	CVS	research.	The	Food	and	Drug	Administration	
(FDA)	could	provide	direction	to	conduct	of	clinical	trials	 in	CVS	
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with	 publication	 of	 appropriate	 advisory	 guidelines.	 As	 an	 ex‐
ample,	 a	document	was	 released	 to	describe	FDA	 recommenda‐
tions regarding trial design in gastroparesis including definition 
of primary and secondary outcome measures, trial duration, and 
subject recruitment protocols (www.fda.gov/downl oads/Drugs/ 
Guida nceCo mplia nceRe gulat oryIn forma tion/Guida nces/UCM45 
5645.pdf).
Finally, patient advocacy groups must remain active to keep the 
spotlight on CVS care and research. The diagnosis of CVS is often 
delayed for an inordinate period of time. Consequently, patients 
and their families are caught in a downward spiral of misunder‐
standing and endless, repetitive diagnostic testing. The value of a 
robust clinical care structure to accurately identify CVS in patients 
with characteristic clinical presentations and to initiate treatment 
in a consistent, evidence‐based fashion cannot be overemphasized. 
However, organized participation by patients is also critical to ad‐
vance research and education in CVS. The Cyclic Vomiting Syndrome 
Association	 (CVSA)	 is	a	non-profit,	 self-help	organization	 that	was	
co-founded	by	Kathleen	Adams	 in	1993.	The	CVSA	plays	a	critical	
role to exchange, support, and disseminate knowledge about CVS 
and promote research in this area. Continued leadership and collab‐
oration	from	the	CVSA	will	be	essential	to	achieve	the	goals	laid	out	
in this article.
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